Stalevo Prostate Cancer Concerns Spark FDA Review
Federal drug reviewers say they have concerns that the side effects of Stalevo, a Parkinson’s disease medication by Novartis, may increase the risk of prostate cancer.
The FDA announced on Wednesday that it has begun a safety review of Stalevo and its potential link to prostate cancer after data from a long-term clinical trial resulted in an unusual number of men developing the disease. The safety review does not mean that the FDA has concluded that there is a causal connection between Stalevo and prostate cancer; only that such a possible link is under investigation.
Stalevo (entacapone/carbidopa/levodopa) is a prescription drug used to treat dyskinesia (movement disorder) associated with the onset of Parkinson’s disease. The drug was approved by FDA in June 2003.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Concerns about Stalevo side effects arose during a 4-year clinical trial called Stalevo Reduction in Dyskinesia Evaluation – Parkinson’s Disease (STRIDE-PD). Researchers looked at 745 patients at 77 centers in 14 countries in a double blind, randomized clinical trial that included 31 sites in the U.S. During the study, 245 men received Stalevo for 2.6 to 4 years. Researchers found that 9 of those men (3.7%) developed prostate cancer, while less than 1% of men not given Stalevo developed prostate cancer during the same time period.
The FDA notes that other trials did not find evidence of a prostate cancer link; however side effects from long-term exposure had never been conducted until the STRIDE-PD trials.
Currently, the FDA is recommending that patients taking Stalevo should continue to do so. The agency is still reviewing the information and will make more information available as it develops during the safety review. The FDA warned healthcare professionals to be aware of the possible Stalevo prostate cancer risk and urged them to follow current guidelines for prostate cancer screening.
AmyMay 6, 2015 at 1:04 am
My Father too has taken stalevo for several years and was diagnosed with prostate cancer. Further studies need to be done on this so that others don't suffer.
aaronJune 25, 2010 at 12:25 pm
i dont have to worry about prostate carcinoma . i had mine removed 6 yrs a,go. it was malignant , i take 5 a day of the 100. im short of breath and have a lot of upper thoratic gas.i tire very easly, im going to haqve a stress test done the 2 ed of july ill let u know the results.also have a lot of flatulance in my lower bowel. no disconfoft but i am a little concerned . i also take 1 azilect a ay[Show More]i dont have to worry about prostate carcinoma . i had mine removed 6 yrs a,go. it was malignant , i take 5 a day of the 100. im short of breath and have a lot of upper thoratic gas.i tire very easly, im going to haqve a stress test done the 2 ed of july ill let u know the results.also have a lot of flatulance in my lower bowel. no disconfoft but i am a little concerned . i also take 1 azilect a ay 1 mg, i seem to be in pretty good health except for the dystonia,,thank u for concern,,
JerryMay 29, 2010 at 11:09 am
Started taking Stalevo in May 2009, diagnosed with prostate cancer Jan. 2010. Would never have taken Stalevo if I had know about the possible increased risk of getting prostate cancer, as I was already at greater risk due to family history of prostate cancer.
"*" indicates required fields
More Top Stories
Uber faces a lawsuit from four passengers who say they were sexually assaulted by drivers, due to the company's lack of security measures and focus on passenger safety.
A Bard PowerPort lawsuit claims the defective design of the port catheter led to a woman developing a severe infection and needing to have the implant surgically removed.
The new federal judge overseeing all talcum powder lawsuits has called for a Science Day to educate the court ahead of planned Daubert hearings which could decide if bellwether test trials can move forward.